Trial Profile
A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Efavirenz; Emtricitabine/tenofovir disoproxil fumarate; Lamivudine/abacavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SPRING-1
- Sponsors ViiV Healthcare
- 30 Apr 2019 Results of post hoc analysis using VL data obtained from the timepoints shared by A5353, SPRING 1 and SINGLE trial published in the Journal of Antimicrobial Chemotherapy
- 07 Mar 2019 Results assessing associated with HOMA-IR (homeostasis model of assessment -insulin resistance) and effect of dolutegravir over time from SPRING-1, STRIIVING, SWORD-1 and -2 trials presented at the 26th Conference on Retroviruses and Opportunistic Infections
- 31 Oct 2018 Results comparing viral decay with dolutegravir plus lamivudine versus dolutegravir-based triple therapy using data from A5353, SPRING-1 and SINGLE (n=588) presented at the 14th International Congress on Drug Therapy and HIV Infection